Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 76.9 kDa. The protein migrates as 100-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
SARS-CoV-2 S1 protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) was more than 85% and the molecular weight of this protein is around 120-150 kDa verified by SEC-MALS.
Human ACE2, Fc Tag (Cat. No. AC2-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) with an affinity constant of 67.6 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human ACE2, Fc Tag (Cat. No. AC2-H5257) on Protein A Biosensor, can bind SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) with an affinity constant of 33.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum
Authors: Fiedler S, Piziorska MA, Denninger V, et al.
Journal: ACS infectious diseases 2021
Application: Binding Assay
Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries. BioRxiv preprint. doi: doi: https://doi.org/10.1101/2020.06.06.137513
Authors: Yan Lou, Wenxiang Zhao, Haitao Wei, et al
Journal: BioRxiv 2020
Application: BLI
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.
A-Z
